MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
- 26 November 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (22), 2591-2595
- https://doi.org/10.1182/blood.2019002943
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussionBlood Cancer Journal, 2018
- Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutationsBlood, 2008
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosisLeukemia, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersBlood, 2006
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005